Sangamo BioSciences | SGMO - Gross Profit On Sales


Sangamo BioSciences reported -2.39M in Gross Profit on Sales for its fiscal quarter ending in June of 2024.





Gross Profit On Sales Change Date
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
Amgen USD 5.87B 1.02B Mar/2026
Bayer EUR 6.33B 1.84B Jun/2026
BioCryst Pharmaceuticals USD 214.41M 61.36M Jun/2026
Biogen USD 2.12B 307M Jun/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Cipla INR 44.1B 5B Jun/2026
Clal Biotechnology ILS -857K 1.42M Jun/2022
Compugen USD 352K 63.44M Mar/2026
CSL USD 4.46B 2.71B Dec/2025
Gilead Sciences USD 6.8B 1.29B Jun/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
Grifols EUR 766.49M 39.74M Dec/2024
Ionis Pharmaceuticals USD 265M 22M Jun/2026
J&J USD 18.55B 1.31B Jun/2026
Karyopharm Therapeutics USD 33.72M 1.13M Mar/2026
Merck USD 12.09B 1.24B Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Omeros USD -33.16M 18.52M Jun/2024
Pfizer USD -248M 11.29B Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.71B 602M Jun/2026
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
Tectonic Therapeutic USD 0 0 Mar/2025
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026